Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „moderate“
Suchtreffer
Begriffe & Kennungen
Ablymico · 4.8 · Gastrointestinal adverse reactions Most episodes of gastrointestinal events were mild to moderate, transient a
Eintrag öffnenAblymico · 4.8 · Patients with mild or moderate renal impairment (creatinine clearance ≥ 30 mL/min) may experience more gastroi
Eintrag öffnenAdempas · 4.5 · Concomitant use with CYP3A4 inducers Bosentan, reported to be a moderate inducer of CYP3A4, led to a decrease
Eintrag öffnenAdempas · 4.5 · Concomitant use with CYP3A4 inducers Bosentan, reported to be a moderate inducer of CYP3A4, led to a decrease
Eintrag öffnenAdtralza · 4.8 · The safety of tralokinumab was assessed in patients 12 to 17 years of age (adolescents) with moderate-to-sever
Eintrag öffnenAfinitor · 4.5 · 9 Potent and moderate CYP3A4 inducers Rifampicin AUC ↓63% Avoid the use of concomitant (range 0-80%) potent CY
Eintrag öffnenAfinitor · 4.5 · Everolimus is a substrate of CYP3A4, and also a substrate and moderate inhibitor of PgP. Therefore, absorption
Eintrag öffnenAlimta · 4.5 · In patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min), the concomi
Eintrag öffnenAloxi · 4.8 · In paediatric clinical trials for the prevention of nausea and vomiting induced by moderately or highly emetog
Eintrag öffnenAmlodipine / Valsartan Mylan · 4.5 · CYP3A4 inhibitors Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors
Eintrag öffnenAnalgosedierung
Eintrag öffnenAptivus · 4.3 · Patients with moderate or severe (Child-Pugh B or C) hepatic impairment.
Eintrag öffnenAptivus · 4.8 · Most frequently reported moderate or severe adverse reactions in paediatric patients aged 12 to 18 years who t
Eintrag öffnenArava · 4.3 · • Patients with moderate to severe renal insufficiency, because insufficient clinical experience is available
Eintrag öffnenArava · 4.3 · • Patients with moderate to severe renal insufficiency, because insufficient clinical experience is available
Eintrag öffnenArava · 4.3 · • Patients with moderate to severe renal insufficiency, because insufficient clinical experience is available
Eintrag öffnenArexvy · 4.8 · Across the three studies, these adverse reactions were usually mild or moderate in intensity and resolved with
Eintrag öffnenAvamys · 4.8 · Epistaxis *Epistaxis was generally mild to moderate in intensity. In adults and adolescents, the incidence of
Eintrag öffnenBalversa · 4.5 · Moderate CYP2C9 or strong CYP3A4 inhibitors Co-administration with a moderate CYP2C9 or strong CYP3A4 inhibito
Eintrag öffnenBalversa · 4.5 · Strong or moderate CYP3A4 inducers Co-administration with carbamazepine, a strong CYP3A4 and weak CYP2C9 induc
Eintrag öffnen